Pioglitazone potassium
Based on 49 publication(s) in Google Scholar
Pioglitazone (U 72107) potassium is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium can be used in diabetes research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 1266523-09-4
- Formel: C19H19KN2O3S
- Molecular Weight:394.53
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-13956
PioglitazonePPARγ Agonist -
HY-17386
RosiglitazonePPARγ Agonist -
HY-143228
SH-42DHCR24 Inhibitor -
HY-B0258
GemfibrozilCytochrome P450 Inhibitor -
HY-14600
Rosiglitazone maleatePPARγ Activator -
HY-17386R
Rosiglitazone (Standard)PPARγ Agonist -
HY-B0258R
Gemfibrozil (Standard) -
HY-50935
TroglitazonePPARγ Agonist -
HY-W738465
N,N-Dimethylamidino UreaEndogenous metabolite -
HY-116215
2-NBDGFluorescent Indicator -
HY-129630
TetrahydrocortisolMetabolite of Hydrocortisone -
HY-13956R
Pioglitazone (Standard)PPARγ Agonist
Publications Citing Use of MedChemExpress (MCE) Pioglitazone potassium
More- Cell Metab. 2021 Mar 2;33(3):581-597.e9. [Abstract]
- Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9. [Abstract]
- Cancer Res. 2022 Apr 15;82(8):1503-1517. [Abstract]
- Nat Commun. 2025 Sep 10;16(1):8215. [Abstract]
- J Adv Res. 2025 Aug:74:429-442. [Abstract]
- Cardiovasc Diabetol. 2026 Jan 14;25(1):38.
- Gut Microbes. 2022 Jan-Dec;14(1):2139978. [Abstract]
- Adv Sci (Weinh). 2026 Jun 22:e24167. [Abstract]
- Adv Sci (Weinh). 2025 Nov 11:e08957. [Abstract]
- Adv Sci (Weinh). 2025 Feb;12(7):e2407134. [Abstract]
- Adv Sci (Weinh). 2024 Nov;11(44):e2401931. [Abstract]
- Cell Death Differ. 2026 Jun 13. [Abstract]
- Chem Eng J. 2026 Feb 24.
- Acta Pharmacol Sin. 2026 Jul 27.
- Acta Pharmacol Sin. 2021 Jan;42(1):160-170. [Abstract]
- Sci China Chem. 2025 Jun 30.
- Am J Chin Med. 2025;53(1):251-283. [Abstract]
- Br J Pharmacol. 2021 Jun;178(11):2305-2323. [Abstract]
- Drug Deliv Transl Res. 2026 Aug 21.
- J Ethnopharmacol. 2025 Jan 31:340:119128. [Abstract]
- Biochem Pharmacol. 2025 Oct:240:117120. [Abstract]
- Eur J Pharmacol. 2026 Jul 15:1030:179101.
- Eur J Pharmacol. 2025 Sep 15:1003:177943. [Abstract]
- Inflammation. 2026 Aug 19.
- Immunology. 2023 Jul;169(3):271-291. [Abstract]
- Ann Med. 2026 Jun 19;58(1).
- Sci Rep. 2026 Mar 31. [Abstract]
- Biol Proced Online. 2025 Jun 16;27(1):21. [Abstract]
- iScience. 2026 Mar 5;29(4):115247. [Abstract]
- Ann N Y Acad Sci. 2026 Mar;1557(1):e70224. [Abstract]
- Poult Sci. 2026 Jan 18;105(4):106481. [Abstract]
- BMC Complement Med Ther. 2022 Jul 1;22(1):176. [Abstract]
- Am J Physiol Heart Circ Physiol. 2021 Jun 1;320(6):H2222-H2239. [Abstract]
- Nutr Metab. 2019 Mar 5:16:17. [Abstract]
- Biochem Eng J. 2021, 108104.
- Am J Physiol Renal Physiol. 2019 Jul 1;317(1):F137-F151. [Abstract]
- J Integr Neurosci. 2026 Apr 13;25(4):47364. [Abstract]
- Food Chem Toxicol. 2021 Jun:152:112183. [Abstract]
- J Steroid Biochem Mol Biol. 2023 May:229:106265. [Abstract]
- Immunopharmacol Immunotoxicol. 2021 Dec;43(6):704-712. [Abstract]
- PLoS One. 2025 Dec 12;20(12):e0337906. [Abstract]
- Med Sci Monit. 2019 Nov 13:25:8544-8553. [Abstract]
- SSRN. 2025 Jul 8.
- Res Sq. 2024 Jul 12.
- Tunku Abdul Rahman University. 2024 Mar 11.
- SSRN. 2023 May 30.
- Heliyon. 2023 Apr 1;9(4):e15146. [Abstract]
- Oxid Med Cell Longev. 2022 Dec 5:2022:2226168. [Abstract]
- Research Square Preprint. 2021 Mar.
Customer Validation & Images
-
WB
-
IF
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
RT-PCR
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
mouse PPARγ 0.99 μM (EC50) |
h-PPARγ 0.93 μM (EC50) |
hPPARδ 43 μM (EC50) |
hPPARα 100 μM (EC50) |
mouse PPARα 100 μM (EC50) |
In Vitro
Pioglitazone potassium (0.5 or 1 μM, 5 days) can completely prevent AGEs (advanced glycation end-products)-induced β-cell necrosis and the increase of caspase-3 thereby avoiding the impaired viability caused by AGEs in pancreatic beta cell line HIT-T15[2].
Pioglitazone potassium (1 μM, 1 h) can stimulate insulin secretion induced by low glucose concentration and attenuate the GSSG/GSH ratio in cells cultured with AGEs[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Pioglitazone potassium (oral gavage, 10 mg/kg, once daily, 4 weeks) can significantly reduce body weight (BW), cardiac hypertrophy, elevated blood glucose levels and improve the associated dyslipidemia[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ob/ob and adipo-/- ob/ob mice with a C57Bl/6 background[3]
-
Dosage:10 or 30 mg/kg
-
Administration:Oral gavage; once daily; 14 days
-
Result:Showed no changes of serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo-/- ob/ob C57BL/6 mice at 10 mg/kg but significantly reduced to a similar degree at 30 mg/kg.
Also showed no changes of expressions of TNFα and resistin in adipose tissues of ob/ob and adipo-/- ob/ob mice at 10 mg/kg but decreased at 30 mg/kg.
-
Animal Model:Male Wistar albino rats[4]
-
Dosage:10 mg/kg
-
Administration:Oral gavage; once daily; 4 weeks
-
Result:Decreased the elevated serum levels of both creatinine and creatine kinase-MB (CK-MB), TGF-β1 gene expression and regulated the expression of MMP-2/TIMP-2 system.
Chemical Information
-
CAS. Nr. 1266523-09-4
-
Molecular Weight 394.53
-
Formel C19H19KN2O3S
-
SMILES
CCC1=CC=C(N=C1)CCOC2=CC=C(C=C2)CC(SC([N-]3)=O)C3=O.[K+]
-
Synonyms
U 72107 potassium
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (49)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
2021 Mar 2;33(3):581-597.e9. PMID: 33440166 -
Cell Stem Cell
Hepatic cytochrome P450 8B1 and cholic acid potentiate intestinal epithelial injury in colitis by suppressing intestinal stem cell renewal. [Abstract]2022 Sep 1;29(9):1366-1381.e9. PMID: 36055192
Pioglitazone potassium purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9. [Abstract]
Crypts isolated from Lgr5-EGFP-IRES-creERT2 mice were cultured with CA together with/without 100 μM WY14643/ 10 μM Pioglitazone/ 1 μM GW501516 for 6 days. Representative staining pattern of Lgr5+ cells.
-
Cancer Res
Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer. [Abstract]2022 Apr 15;82(8):1503-1517. PMID: 35255118 -
Nat Commun
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. [Abstract]2025 Sep 10;16(1):8215. PMID: 40931013
Pioglitazone potassium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 10;16(1):8215. [Abstract]
Western blot for NECTIN4 and HPGD in RT112 cells treated with T0070907, Rosiglitazone, and Pioglitazone (1 μM, 72 h).
-
J Adv Res
Gastrodin attenuates high fructose-induced sweet taste preference decrease by inhibiting hippocampal neural stem cell ferroptosis. [Abstract]2025 Aug:74:429-442. PMID: 39353531 -
-
Gut Microbes
FABP4 in Paneth cells regulates antimicrobial protein expression to reprogram gut microbiota. [Abstract]2022 Jan-Dec;14(1):2139978. PMID: 36519446 -
Adv Sci (Weinh)
Lilrb4a Suppression Reprograms Microglia to Mitigate APOE4-Associated Amyloid Plaques and Cerebral Amyloid Angiopathy in Association With a PPAR-Linked Pro-Clearance State. [Abstract]2026 Jun 22:e24167. PMID: 42330346 -
Adv Sci (Weinh)
Mitochondrial CISD1 Modulates Microglial Metabolic Reprogramming to Drive Stress Susceptibility in Mice. [Abstract]2025 Nov 11:e08957. PMID: 41215712
Pioglitazone potassium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 11:e08957. [Abstract]
Experimental timelines for behavioral testing following Pioglitazone (15-30 mg/kg, p.o.) treatment. Typical heat plot , social interaction ratio, time in interaction zone.
Pioglitazone potassium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 11:e08957. [Abstract]
The mRNA expression of inflammatory cytokines Il1b and Il6 decreased in the mPFC from control‐GFP, SUS‐GFP, control‐Pioglitazone and SUS‐Pioglitazone (15-30 mg/kg, p.o.) mice.
-
Adv Sci (Weinh)
Fatty Acid Oxidation-Glycolysis Metabolic Transition Affects ECM Homeostasis in Silica-Induced Pulmonary Fibrosis. [Abstract]2025 Feb;12(7):e2407134. PMID: 39721015
Pioglitazone potassium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Feb;12(7):e2407134. [Abstract]
Decreased expression of collagen I in activated fibroblasts was consistently shown through immunofluorescence staining after administering 3PO and Pioglitazone (10, 20, 30 μM).
Pioglitazone potassium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Feb;12(7):e2407134. [Abstract]
Histopathological analysis of mouse lung tissue revealed that treatment with Pioglitazone (10, 20, 30 μM) partially mitigated lung fibrosis, although collagen deposits persisted.
-
Adv Sci (Weinh)
The Thyroid Hormone Analog GC-1 Mitigates Acute Lung Injury by Inhibiting M1 Macrophage Polarization. [Abstract]2024 Nov;11(44):e2401931. PMID: 39373388 -
Cell Death Differ
TRIM17 downregulation modulates CRPC progression and enzalutamide resistance by derepressing BCL2 expression via the p53-dependent and p53-independent pathways. [Abstract]2026 Jun 13. PMID: 42288623 -
-
-
Acta Pharmacol Sin
2021 Jan;42(1):160-170. PMID: 32541921 -
-
Am J Chin Med
Berberine Inhibited SASP-Related Inflammation through RXRα/PPARγ/NEDD4 Pathway in Atherosclerosis. [Abstract]2025;53(1):251-283. PMID: 39829230 -
Br J Pharmacol
2021 Jun;178(11):2305-2323. PMID: 33591571 -
-
J Ethnopharmacol
Serum metabolomics and 16S rRNA amplicon sequencing reveal the role of puerarin in alleviating bone loss aggravated by antidiabetic agent pioglitazone in type 2 diabetic mice. [Abstract]2025 Jan 31:340:119128. PMID: 39617084 -
Biochem Pharmacol
Dual inhibition of EGR1/STAT3 transcriptional hubs suppresses macrophage-driven liver fibrosis: A multi-omics-guided drug repurposing strategy. [Abstract]2025 Oct:240:117120. PMID: 40623460 -
-
Eur J Pharmacol
2025 Sep 15:1003:177943. PMID: 40653078 -
-
Immunology
Inactivation of mitochondrial pyruvate carrier promotes NLRP3 inflammasome activation and gout development via metabolic reprogramming. [Abstract]2023 Jul;169(3):271-291. PMID: 36708143 -
-
Sci Rep
Pomolic acid alleviates CCl4‑induced liver fibrosis in mice by suppressing β-arrestin 2-mediated pro-fibrotic macrophage polarization. [Abstract]2026 Mar 31. PMID: 41917130 -
Biol Proced Online
Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening. [Abstract]2025 Jun 16;27(1):21. PMID: 40524168 -
iScience
2026 Mar 5;29(4):115247. PMID: 41907401 -
Ann N Y Acad Sci
The TRIB1-PPARγ Axis Regulates Cholesterol Metabolism in Pancreatic Ductal Adenocarcinoma. [Abstract]2026 Mar;1557(1):e70224. PMID: 41774091 -
Poult Sci
Three alternative promoters govern PGC-1α expression in chicken and are directly repressed by PPARγ. [Abstract]2026 Jan 18;105(4):106481. PMID: 41610606 -
BMC Complement Med Ther
Luteolin alleviates inflammation and autophagy of hippocampus induced by cerebral ischemia/reperfusion by activating PPAR gamma in rats. [Abstract]2022 Jul 1;22(1):176. PMID: 35778706 -
Am J Physiol Heart Circ Physiol
Periostin promotes arterial calcification through PPARγ-related glucose metabolism reprogramming. [Abstract]2021 Jun 1;320(6):H2222-H2239. PMID: 33834866 -
Nutr Metab
Aerobic exercise decreases chemerin/CMKLR1 in the serum and peripheral metabolic organs of obesity and diabetes rats by increasing PPARγ. [Abstract]2019 Mar 5:16:17. PMID: 30873215 -
-
Am J Physiol Renal Physiol
Pioglitazone decreased renal calcium oxalate crystal formation by suppressing M1 macrophage polarization via the PPAR-γ-miR-23 axis. [Abstract]2019 Jul 1;317(1):F137-F151. PMID: 31091119 -
J Integr Neurosci
Roles of Metformin and Pioglitazone in Regulating A1-like Astrocyte Activation in EAE Mice. [Abstract]2026 Apr 13;25(4):47364. PMID: 42052770 -
Food Chem Toxicol
PPAR-γ with its anti-fibrotic action could serve as an effective therapeutic target in T-2 toxin-induced cardiac fibrosis of rats. [Abstract]2021 Jun:152:112183. PMID: 33836209 -
J Steroid Biochem Mol Biol
Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α. [Abstract]2023 May:229:106265. PMID: 36737028 -
Immunopharmacol Immunotoxicol
Mechanism of neuroprotective effect of stevioside on cerebral ischemia-reperfusion injury via PPAR-γ activation. [Abstract]2021 Dec;43(6):704-712. PMID: 34448677 -
PLoS One
Investigation of the effect and mechanisms of moxa smoke in the treatment of Influenza A Virus (IAV) infection. [Abstract]2025 Dec 12;20(12):e0337906. PMID: 41385483 -
Med Sci Monit
Gegen Qinlian Decoction Ameliorates Hepatic Insulin Resistance by Silent Information Regulator1 (SIRT1)-Dependent Deacetylation of Forkhead Box O1 (FOXO1). [Abstract]2019 Nov 13:25:8544-8553. PMID: 31719515 -
-
-
-
-
Heliyon
Combined therapy with pioglitazone and FGF21 mRNA synergistically ameliorates metabolic disorders in NAFLD rats. [Abstract]2023 Apr 1;9(4):e15146. PMID: 37123911 -
Oxid Med Cell Longev
Qihuang Zhuyu Formula Attenuates Atherosclerosis via Targeting PPAR γ to Regulate Cholesterol Efflux and Endothelial Cell Inflammation. [Abstract]2022 Dec 5:2022:2226168. PMID: 36518993 -
Reinheit & Dokumentation
Verweise
[1]. Kenji Kuwabara, et al. A novel selective peroxisome proliferator-activated receptor alpha agonist,2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice. J Pharmacol Exp Ther. 2004 Jun;309(3):970-7. [Content Brief]
[2]. A Puddu, et al. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177(1-3):79-84. [Content Brief]
[3]. Naoto Kubota, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281(13):8748-55. [Content Brief]
[4]. Rania A Elrashidy, et al. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Pioglitazone potassium Related Classifications
HY-13956B Related Classifications
Powered by Bioz